AstraZeneca second dose doesn't raise risk of rare blood clots


FILE PHOTO: Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration

BENGALURU: AstraZeneca's Covid-19 shot did not increase the instances of rare blood clots with low platelets in people after the second dose, a study showed on Wednesday, potentially easing some worries over the vaccine's side-effects.

Data published in the Lancet medical journal found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, AstraZeneca said https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose.html.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Wall St set to open higher on tech boost, PCE data
US inflation rises in line with expectations in March
Gamuda Land announces retail partners for Gamuda Gardens
YNH reaffirms bondholders with remedied technical defaults
Ringgit ends firmer against US dollar
KPJ Healthcare partners with Trustr for AI-driven healthcare solutions
Homeritz stays positive amid economic challenges
Unisem expects performance boost amid semiconductor recovery
Gadang wins RM280mil data centre contract
S P Setia unveils Casaville single-storey bungalows in Setia EcoHill, Semenyih

Others Also Read